These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1057 related articles for article (PubMed ID: 26967052)

  • 1. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
    Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
    Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
    Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
    Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PI3K/AKT Pathway as a Target for Cancer Treatment.
    Mayer IA; Arteaga CL
    Annu Rev Med; 2016; 67():11-28. PubMed ID: 26473415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
    Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
    World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
    Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
    BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
    Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding.
    Sami A; Karsy M
    Tumour Biol; 2013 Aug; 34(4):1991-2002. PubMed ID: 23625692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
    Sun Z; Wang Z; Liu X; Wang D
    Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of EGFR, PI3K, AKT, and mTOR in heavy metal-induced cancer.
    Carpenter RL; Jiang BH
    Curr Cancer Drug Targets; 2013 Mar; 13(3):252-66. PubMed ID: 23297824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the AKT pathway in glioblastoma.
    McDowell KA; Riggins GJ; Gallia GL
    Curr Pharm Des; 2011; 17(23):2411-20. PubMed ID: 21827416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
    Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
    Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma.
    Guo T; Wu C; Zhang J; Yu J; Li G; Jiang H; Zhang X; Yu R; Liu X
    Cell Commun Signal; 2023 Dec; 21(1):363. PubMed ID: 38115126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphoinositide-3 kinase/protein kinase-B/mammalian target of rapamycin pathway in psoriasis pathogenesis. A potential therapeutic target?
    Huang T; Lin X; Meng X; Lin M
    Acta Derm Venereol; 2014 Jul; 94(4):371-9. PubMed ID: 24217655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
    Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
    J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.
    Papadimitrakopoulou V
    J Thorac Oncol; 2012 Aug; 7(8):1315-26. PubMed ID: 22648207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway.
    Wilks ST
    Breast; 2015 Oct; 24(5):548-55. PubMed ID: 26187798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
    Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
    Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.